德国专利药早期效益评估与价格管理关键点探究

Research on Key Points of Early Benefit Assessment and Price Management Concerning German Patent Medicines

卫生技术评估越来越多地被用于健康产品的价值评估并决定资源如何最大化利用。文章详细介绍了德国专利药价格管理历程、AMONG法案的主要内容及AMONG法案下早期效益评估与价格协商谈判的关键要点,为我国创新药医保目录准入与动态调整决策中应用卫生技术评估提供参考。

Health technology assessments are increasingly used to evaluate the value of health products and determine how to maximize the use of resources.It introduces the history of German patent drug price management,the main content of the AMONG act,and the key points concerning early benefit assessment and price negotiation under the AMONG act,so as to provide references for the application of health technology assessment in national medical insurance directory access and dynamic adjustment decisions.